Mediacenter

Research Report: The Future Of The Pharmaceutical Supply Chain

With a large number of blockbuster drugs’ patents expiring in recent years, pharma companies are seeing a significant increase in complexity and risk in their supply chains. Supply chains are shifting from traditional small, molecule, and solid dose products to more bio-engineered, complex, and technical products. These are niche products with a shorter shelf life that require a more sophisticated cold-chain and temperature controlled supply chain with a very specialized customer and patient in mind. This paper addresses how to overcome some of these challenges based on two VIP Think Tank discussions based 6 months apart in New Jersey as part of the LogiPharma USA conference.